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Abstract
Bone marrow (BM) involvement in diffuse large B-cell lymphoma (DLBCL) can be
morphologically discordant from the primary tumor. Concordant BM inﬁltration has
been shown associated with a poorer outcome in patients treated with CHOP. In order to
evaluate tumor-related factors leading to BM involvement in DLBCL, we performed an
integrated analysis of i) genomic proﬁles obtained with a high-density genome wide SNP-
based arrays ii) immunomorphological and iii) clinical data from 133 patients uniformly
treated with R-CHOP. BM inﬁltration was found in 27 of 133 (20%) cases; and it was
concordant in 18/27 (67%) cases. Concordant inﬁltration, but not discordant, inﬂuenced
negatively OS, PFS and DFS and was associated with higher serum LDH, lower CR and
higher PD rates. No association with cell of origin was found between BMþ and BM-
DLBCL. As compared with BM- cases, BMþ DLBCL showed absence of 7q gain.
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Introduction
Bone marrow (BM) involvement occurs in 10–30% of
diffuse large B-cell lymphoma (DLBCL) [1,2]. In up to
70% of the cases, BM inﬁltration can be morphologically
and immunomorphologically discordant from the primary
tumour, mainly reﬂecting features of a low grade B-cell
lymphoma. In clonally related cases, transformation from a
low-grade B-NHL can be assumed, whereas the presence
of a second coexisting B-cell neoplasm should be
considered in clonally unrelated cases [2–4]. An important
impact of concordant BM involvement on overall survival
(OS), independent of the IPI, has been previously observed
in patients treated with CHOP [1,2]. In concordant cases,
the percentage of neoplastic B-cells as well as the
proportion of hematopoietic tissue involved have also a
prognostic signiﬁcance [5]. The molecular mechanisms
leading to BM involvement by DLBCL are largely
unknown and may include tumour- and host-related
factors. In order to partially elucidate the role of
tumour-related parameters we analyzed clinical data and
genomic proﬁles obtained with high-density genome-wide
microarrays in DLBCL patients treated with R-CHOPwith
and without BM involvement.
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Methods
Cases with the information on BM involvement were
identiﬁedwithina series of 166 consecutivecasesofDLBCL
[6], selected based upon the availability of frozen material,
for having a fraction of malignant cells in the pathological
specimen representing >70% of overall cellularity as
determined by morphological and immunophenotypic
studies. The study was approved by the Bellinzona ethical
committee.
In patients with BM inﬁltration, BM samples and ﬂow
cytometry images obtained at time of initial diagnosis
were reviewed and compared with the primary DLBCL
biopsies. In doubtful cases, immunohistochemistry (IHC)
was repeated and benign lymphoid inﬁltrates were
excluded, according to earlier published criteria [7].
BM Inﬁltration by large CD20þ cells was deﬁned as
concordant, while by small or mixed-small and large
CD20þ cells as discordant. No information regarding
possible clonal relationships of the discordant BM-
component with the primary DLBCL tumours was
available. The cell of origin (COO), germinal centre B-
cell-like (GCB) or non-GCB types was deﬁned in 84
cases, using IHC in 45 according to the algorithm of Hans
et al. [8] and with gene expression proﬁles (GEPs) in 39
samples [9].
Genomic proﬁles were obtained with the GeneChip
Human Mapping 250K NspI (Affymetrix, Santa Clara, CA,
USA), as previously reported [6,10]. ThemodiﬁedBayesian
Piecewise Regression (mBPCR) method [11] was used to
estimate the copy number (CN) starting from rawCNvalues
obtainedwithAffymetrixCNAT4.01. Forminimal common
regions (MCRs) [12] occurring in at least 15% of cases,
differences in frequencies between subgroups were eval-
uated using Fisher’s exact test: no adjustments for multiple
test correctionweremadedue to the exploratorynatureof the
study. OS, progression free survival (PFS), disease free
survival (DFS) and response criteria were deﬁned according
toCheson et al. [13]. The actuarial duration of PFS,DFS and
OS were plotted according to the Kaplan–Meier method.
Univariate analysis was performed with the Log-Rank test.
Chi-square test was used to compare differences in clinical
parameters. A p-value<0.05 was considered as statistically
signiﬁcant. Statistical analyses were performed with SPSS
17.0.1 (SPSS, Chicago, IL, USA) and R statistical package.
Results and discussion
BM involvement was observed in 27/133 (20%) of the
patients. The inﬁltration was concordant in 18/27 (67%)
and discordant in 9/27(33%) cases (Figure 1). All
Figure 1. Pattern of BM involvement in DLBCL: morphology and clinical outcome. (A) Example of discordant BM involvement, H&E
40. (B) Example of concordant BM involvement, H&E 40. (C) Overall survival according to BM-status in 12 patients with a
concordant pattern (green), six with discordant pattern (yellow) and 104 without any involvement (blue) (p< 0.001).
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discordant cases were CD5 negative. Only one patient
resulted in having a history of a pre-existing low-grade B-
cell lymphoma (follicular lymphoma, FL) transformed to
DLBCL, and indeed morphological features of FL (grade
I-II) in BM. Clinical characteristics at time of diagnosis,
reﬂecting the general population of DLBCL patients [14],
are listed in Supplementary Table I. No statistically
signiﬁcant differences in terms of COOwas found between
BMþ and BM DLBCL.
Patients with concordant BM inﬁltration were younger
than all the remaining cases, presented poorer parameters
such as LDH serum values, lower complete response rate
and higher rate of progression or relapse. Patients with
discordant BM involvement presented characteristics
similar to patients without any BM inﬁltration.
Univariate analysis according to OS (Figure 1), PFS and
DFS showed that, also for patients treated with R-CHOP,
concordant BM involvement inﬂuenced survival negatively
(p< 0.001), whereas no events were observed among
patients with discordant involvement. These data further
support the importance of precisely reporting the pattern of
BM involvement in the clinical practice, since the presence
of a small cell component does not seem to affect the
outcome.
The genomic aberrations detected in the whole group
of 133 cases reﬂected what has already been reported in
DLBCL [6,12,15,16]. The analysis of genomic aberra-
tions further highlighted that cases with concordant BM
inﬁltration are biologically different (Figure 2). When
compared to the patients without BM involvement,
patients with concordant BM inﬁltration completely
lacked the otherwise common gains of the whole
chromosome 7 or of its long arm (p-value¼ 0.04), and
also presented a much lower frequency of losses affecting
the 6q and in particular the 6q13-q27 region, containing
PRDM1 and TNFAIP3 (p-value¼ 0.04). On the converse,
other common aberrations, such as deletions at 1p or 17p
or gains of chromosome 12 or occurring in the long arms
of chromosomes 1, 11 and 18 were observed in both
groups of patients. No differences were observed in terms
LOH. Due to their small number, we did not perform
statistical analyses on the group of patients with
discordant BM inﬁltration.
Gain of 7q is a common genetic lesion among DLBCL,
possibly more common in GCB than in non-GCB type,
whereas 6q deletion is more frequent in non-GCB
DLBCL [12,17,18]. Up to now, none of the two genomic
aberrations have been described in relationship with BM
localization. Based upon the literature, DLBCL cases
with double translocations affecting BCL2 and CMYC
have a higher tendency for BM involvement [19].
Interestingly, cases with single translocations of CMYC
do not seem to have a high rate of BM involvement
despite a poor outcome [20], and, indeed, often present
gains of chromosome 7 [21]. Gains of 7q gain seem to
occur at similar percentage among DLBCL arising from
both immune-privileged and immune-competent anatom-
ical sites [22]. The presence of gains at 7q have been
associated with a reduced T-cell inﬁltrate [23].
In conclusion, DLBCL with concordant BM inﬁltration
showed distinct clinical and biological features. Only
concordantBM inﬁltrationhad a negative impact on survival
in patients with DLBCL, also when treated with R-CHOP.
We provided evidence that 7q gain were never observed in
primary tumour samples from these patients.
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Figure 2. Frequency of gains (up, red) and losses (down, blue) in DLBCL patients according to bone marrow involvement. X-axis,
chromosome localization and physical mapping; Y-axis, percentage of cases bearing the aberration. Arrows: The two regions showing
signiﬁcant differences between cases without BM involvement and cases with concordant BM involvement. Upper panel: Frequency of
DNA gains and losses observed in 106 cases without BM-involvement. Intermediate panel: Frequency of DNA gains and losses observed
in all 27 cases with BM-involvement. Lower panel: Frequency of DNA gains and losses observed in 18 cases with concordant BM-
involvement.
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